GoHealth マネジメント
マネジメント 基準チェック /14
GoHealthの CEO はVijay Kotteで、 Jun2022年に任命され、 の在任期間は 3.92年です。 の年間総報酬は$ 13.76Mで、 7%給与と93%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の5.69%を直接所有しており、その価値は$ 1.09M 。経営陣と取締役会の平均在任期間はそれぞれ3.1年と0.8年です。
主要情報
Vijay Kotte
最高経営責任者
US$13.8m
報酬総額
| CEO給与比率 | 7.05% |
| CEO在任期間 | 3.9yrs |
| CEOの所有権 | 5.7% |
| 経営陣の平均在職期間 | 3.1yrs |
| 取締役会の平均在任期間 | less than a year |
経営陣の近況
Recent updates
ナラティブの更新 • Apr 30
GOCO: Lower P E And Improved Revenue Outlook Will Support Returns
Analysts have cut their 12 month price target for GoHealth by about $3, reflecting a reset in fair value assumptions along with updated views on revenue growth, margins and future P/E, following a recent downgrade highlighted in Street research. Analyst Commentary Bearish analysts are framing the latest downgrade as part of a broader reset in expectations for GoHealth, with the lower 12 month price target seen as a response to questions about how quickly the business can translate its model into consistent, scalable earnings.
ナラティブの更新 • Apr 14
GOCO: Lower Earnings Multiple Will Support Upside Despite Nasdaq Compliance Risk
Analysts cut their GoHealth price target from $7.70 to $4.70 as they factor in updated assumptions for revenue growth and margins, and incorporate the recent downgrade at Freedom Broker into their outlook. Analyst Commentary Bullish Takeaways Bullish analysts view the reset to a US$4.70 target as a cleaner entry point that better reflects current expectations for revenue growth and margins, which they see as more achievable under updated assumptions.ナラティブの更新 • Mar 31
GOCO: Discount Rate Tweaks Will Support Upside Despite Nasdaq Compliance Risk
Analysts have nudged up their price target on GoHealth to $7.70, citing a slightly lower discount rate and modest tweaks to long term revenue growth, profit margin, and future P/E assumptions as key drivers of the change. What's in the News On March 18, 2026, GoHealth received a notice from Nasdaq that it is not in compliance with the minimum US$35 million market value of listed securities requirement under Listing Rule 5550(b)(2) (Nasdaq filing).ナラティブの更新 • Mar 17
GOCO: Stable Assumptions And Low Future P E Will Support Returns
Analysts have kept their GoHealth price target unchanged at $4.50. They point to only slight tweaks in revenue growth, profit margin and forward P/E assumptions that do not materially alter their overall view of the stock.ナラティブの更新 • Mar 03
GOCO: Stronger Margins And Lower P E Will Support Future Cash Flow
Analysts have trimmed their price target on GoHealth to reflect slightly weaker revenue expectations, a modestly stronger profit margin, and a marginally lower forward P/E. This results in a small downward adjustment in their $ price outlook for the stock.ナラティブの更新 • Feb 17
GOCO: Carrier Relationship Reset Will Support Future Cash Flow Recovery
Analysts have sharply reduced GoHealth's target, with one firm lowering its price target to $5 from $12 after Q3 results came in below expectations because of topline weakness tied to a suspended relationship with a large carrier. Analyst Commentary Bearish analysts are recalibrating their expectations after Q3 results came in well below what they were looking for, and the cut in the price target to $5 from $12 signals a more cautious stance on the stock.ナラティブの更新 • Feb 03
GOCO: Cash Burn Discipline And Carrier Reset Could Support Future Upside
Analysts have cut their price targets on GoHealth, including a reduction to US$5 from US$12. They cited weaker than expected Q3 results tied to topline softness from a suspended carrier relationship, a pullback in new enrollment growth, and ongoing concerns about market headwinds and cash flow sustainability.ナラティブの更新 • Jan 20
GOCO: Cash Discipline And Carrier Reset Will Support Future Cash Flow
Analysts have sharply reduced their GoHealth price targets, with one moving from US$12 to US$5. This reflects weaker Q3 results tied to a suspended carrier relationship, as well as concerns about ongoing market headwinds and cash flow visibility.ナラティブの更新 • Jan 06
GOCO: Focus On Cash Burn Discipline And Carrier Reset Supporting Future Stability
Narrative Update on GoHealth Analysts have cut their 12 month price target for GoHealth to US$5.00 from US$12.00, reflecting weaker Q3 results tied to a suspended relationship with a large carrier, softer revenue and Medicare submissions, a pullback in new enrollment growth, and concerns around ongoing market headwinds and uncertainty about achieving sustainable positive cash flow. Analyst Commentary Recent research updates on GoHealth reflect a cautious reset of expectations following Q3 results that came in below prior estimates, with price targets and ratings adjusted to reflect execution risks and a more uncertain growth outlook.ナラティブの更新 • Dec 15
GOCO: Cash Flow Improvements Will Outweigh Carrier Loss And Enrollment Pullback
Analysts have sharply reduced their price target on GoHealth from approximately $12.00 to about $5.00 per share. This reflects weaker than expected Q3 results, revenue headwinds from a suspended carrier relationship, and persistent concerns about the company's ability to deliver sustainable growth and cash flow in a challenging market.ナラティブの更新 • Dec 01
GOCO: Focus On Profitability And Cash Burn Reduction Will Drive Future Stability
Analysts have sharply reduced GoHealth's fair value estimate from $14 to $7.70 per share. They cite ongoing market headwinds, weaker-than-expected Q3 results, and challenges in revenue growth as key reasons for the downward revision.ナラティブの更新 • Nov 17
GOCO: Recent Credit Move Will Boost Flexibility Ahead of Enrollment Period
Analysts have revised GoHealth's fair value estimate downward from $17.20 to $14.00. This change is due to updated model assumptions and increased caution surrounding revenue growth following recent company results and financial transactions.ナラティブの更新 • Aug 25
Financial Flexibility And M&A Will Unlock Medicare And Senior Health Potential
GoHealth’s price target has been revised downward to $18.40, primarily reflecting reduced expectations for both future earnings multiples and revenue growth. What's in the News GoHealth has formed a Transformation Committee with new board members to evaluate strategic opportunities, including acquisitions, securitizations, and capital structure options.ナラティブの更新 • Aug 10
Financial Flexibility And M&A Will Unlock Medicare And Senior Health Potential
Despite higher revenue growth forecasts, GoHealth’s future P/E multiple has dropped sharply, indicating reduced investor confidence in earnings quality or sustainability, leading to a lower consensus price target of $19.60. What's in the News GoHealth has formed a Transformation Committee to evaluate acquisitions, financial structure options, securitizations, and other strategic opportunities for value creation.
新しいナラティブ • Mar 31
Medicare Engagement And Efficiency Will Drive Future Savings
GoHealth's shift to Medicare engagement enhances consumer relations and boosts operational efficiency, lowering costs and improving margins.Seeking Alpha • May 28
GoHealth: Turning The Corner On Operating Cash Flow
Summary GoHealth's shares have continued to drop despite positive developments, presenting an opportunity for investors to build a position over time. The company has shown positive operating cash flow for five consecutive quarters, reflecting a shift towards profitability and cost containment. Although GOCO previously needed to rely on debt funding, it is now deleveraging, and its focus on operating cash flow is a positive sign for investors. Read the full article on Seeking Alpha分析記事 • May 10
GoHealth, Inc. (NASDAQ:GOCO) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Shareholders will be ecstatic, with their stake up 44% over the past week following GoHealth, Inc. 's ( NASDAQ:GOCO...CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$294m |
| Dec 31 2025 | US$14m | US$969k | -US$261m |
| Sep 30 2025 | n/a | n/a | -US$203m |
| Jun 30 2025 | n/a | n/a | -US$30m |
| Mar 31 2025 | n/a | n/a | -US$2m |
| Dec 31 2024 | US$6m | US$900k | -US$7m |
| Sep 30 2024 | n/a | n/a | -US$33m |
| Jun 30 2024 | n/a | n/a | -US$64m |
| Mar 31 2024 | n/a | n/a | -US$67m |
| Dec 31 2023 | US$5m | US$900k | -US$67m |
| Sep 30 2023 | n/a | n/a | -US$127m |
| Jun 30 2023 | n/a | n/a | -US$132m |
| Mar 31 2023 | n/a | n/a | -US$146m |
| Dec 31 2022 | US$10m | US$485k | -US$150m |
報酬と市場: Vijayの 総報酬 ($USD 13.76M ) は、 US市場 ($USD 626.93K ) の同規模の企業の平均を上回っています。
報酬と収益: Vijayの報酬は増加しましたが、会社は利益を上げていません。
CEO
Vijay Kotte (47 yo)
3.9yrs
在職期間
US$13,757,255
報酬
Mr. Vijay Kumar Kotte serves as Chief Executive Officer & Director of GoHealth, Inc. from June 06, 2022. He served as Executive Vice President, Strategy & Corporate Development and Chief Solutions Officer...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Co-Founder & Non-Executive Co-Chairman | 6.3yrs | US$150.00k | 0.042% $ 8.0k | |
| Co-Founder & Non-Executive Co-Chairman | 6.3yrs | US$150.00k | 0.11% $ 21.6k | |
| CEO & Director | 3.9yrs | US$13.76m | 5.69% $ 1.1m | |
| Chief Financial Officer | 1.6yrs | US$2.06m | 0.42% $ 81.2k | |
| Chief Operating Officer | 2.8yrs | US$2.19m | 1.25% $ 239.5k | |
| Chief Technology Officer | 1.5yrs | データなし | データなし | |
| Vice President of Investor Relations | no data | データなし | データなし | |
| Chief Legal Officer & Corporate Secretary | 2.3yrs | データなし | 0.14% $ 27.3k | |
| Chief Marketing Officer | 3.3yrs | データなし | データなし | |
| Chief People Officer | 3.3yrs | データなし | データなし | |
| Chief Distribution Officer | 1.3yrs | データなし | データなし |
3.1yrs
平均在職期間
47yo
平均年齢
経験豊富な経営陣: GOCOの経営陣は 経験豊富 であると考えられます ( 3.1年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Co-Founder & Non-Executive Co-Chairman | 6.3yrs | US$150.00k | 0.042% $ 8.0k | |
| Co-Founder & Non-Executive Co-Chairman | 6.3yrs | US$150.00k | 0.11% $ 21.6k | |
| CEO & Director | 3.9yrs | US$13.76m | 5.69% $ 1.1m | |
| Independent Director | 4yrs | US$150.00k | 0.58% $ 110.6k | |
| Director | less than a year | US$135.48k | データなし | |
| Director | less than a year | データなし | データなし | |
| Director | less than a year | US$262.74k | データなし | |
| Director | less than a year | US$262.74k | データなし | |
| Director | less than a year | US$262.74k | データなし |
0.8yrs
平均在職期間
55yo
平均年齢
経験豊富なボード: GOCOの 取締役会 は 経験豊富 ではない ( 0.8年の平均在任期間) ため、新しい取締役会が必要であると考えられます。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/25 00:11 |
| 終値 | 2026/05/22 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
GoHealth, Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。16
| アナリスト | 機関 |
|---|---|
| Steven Valiquette | Barclays |
| Steven Valiquette | Barclays |
| Michael Cherny | BofA Global Research |